BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO

BerGenBio to Participate in Investor Webcast and Q&A

BerGenBio ASA: Receipt of subscription rights in the rights issue by primary insiders and their close associates

BerGenBio ASA - Commencement of the subscription period for the rights issue

BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue

BerGenBio Announces Abstracts Accepted for Presentation at 2023 ASCO

BGBIO – Ex. subscription rights today

BerGenBio ASA: Annual general meeting held

BerGenBio ASA – Updated key information relating to the preferential rights issue